Nea Management Company Has Increased By $1.25 Million Its Affimed Nv (AFMD) Holding; Lendingtree Has 0.71 Sentiment

June 13, 2018 - By Natalie Daughtry

LendingTree, Inc. (NASDAQ:TREE) Logo

Nea Management Company Llc increased Affimed Nv (AFMD) stake by 32.14% reported in 2018Q1 SEC filing. Nea Management Company Llc acquired 1.25 million shares as Affimed Nv (AFMD)’s stock rose 3.53%. The Nea Management Company Llc holds 5.14 million shares with $9.51M value, up from 3.89M last quarter. Affimed Nv now has $140.38 million valuation. The stock increased 2.27% or $0.05 during the last trading session, reaching $2.25. About 400,733 shares traded or 12.98% up from the average. Affimed N.V. (NASDAQ:AFMD) has declined 6.38% since June 13, 2017 and is downtrending. It has underperformed by 18.95% the S&P500. Some Historical AFMD News: ; 09/04/2018 – Keytruda is already approved to treat several forms of cancer, including advanced melanoma. The drug racked up $3.81 billion in revenue in 2017; 13/03/2018 – FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) for; 28/03/2018 – Affimed Forms Golden Cross: Technicals; 16/04/2018 – Dynavax Reports Interim Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Squamous Cell; 08/05/2018 – ONCOSEC MEDICAL SAYS UNDER COLLABORATION AGREEMENT, ONCOSEC WILL SPONSOR, FUND STUDY AND MERCK WILL PROVIDE KEYTRUDA; 23/05/2018 – MERCK & CO INC – KEYTRUDA COMBINATION MET DUAL PRIMARY ENDPOINTS OF OVERALL SURVIVAL (OS) AND PROGRESSION-FREE SURVIVAL (PFS) IN STUDY; 17/04/2018 – Dynavax Provides New Durability of Response Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Melanoma at the 2018 American Association for Cancer Research Annual Meeting; 25/05/2018 – Oncolytics Biotech® Announces Research Collaboration with the Keck School of Medicine of USC Combining REOLYSIN® with Keytruda®, Velcade® and Dexamethasone; 23/05/2018 – MERCK & CO’S KEYTRUDA® (PEMBROLIZUMAB) SIGNIFICANTLY IMPROVED; 16/04/2018 – Combination Of Pembrolizumab And Chemotherapy Doubles Survival In Patients With Metastatic Lung Cancer

Lendingtree Inc (TREE) investors sentiment decreased to 0.71 in Q1 2018. It’s down -0.52, from 1.23 in 2017Q4. The ratio worsened, as 86 investment professionals opened new and increased holdings, while 121 cut down and sold positions in Lendingtree Inc. The investment professionals in our database now possess: 9.14 million shares, up from 9.13 million shares in 2017Q4. Also, the number of investment professionals holding Lendingtree Inc in top ten holdings decreased from 7 to 5 for a decrease of 2. Sold All: 28 Reduced: 93 Increased: 53 New Position: 33.

LendingTree, Inc., through its subsidiary, LendingTree, LLC, operates an online loan marketplace for clients seeking loans and other credit offerings in the United States. The company has market cap of $3.06 billion. The firm offers tools and resources, including free credit scores that facilitate comparison shopping for these loans and other credit offerings. It has a 214.82 P/E ratio. The Company’s mortgage products comprise purchase and refinance products.

G2 Investment Partners Management Llc holds 4.82% of its portfolio in LendingTree, Inc. for 37,318 shares. Nikko Asset Management Americas Inc. owns 273,098 shares or 3.19% of their US portfolio. Moreover, Emerald Mutual Fund Advisers Trust has 2.95% invested in the company for 229,122 shares. The Pennsylvania-based Emerald Advisers Inc Pa has invested 2.68% in the stock. Timpani Capital Management Llc, a Wisconsin-based fund reported 20,370 shares.

The stock decreased 8.05% or $21.425 during the last trading session, reaching $244.675. About 650,485 shares traded or 183.74% up from the average. LendingTree, Inc. (TREE) has risen 66.73% since June 13, 2017 and is uptrending. It has outperformed by 54.16% the S&P500. Some Historical TREE News: ; 03/05/2018 – LendingTree Survey Finds Most Small Business Owners Are Using Tax Reform Savings to Pay Off Debt; 26/04/2018 – LendingTree 1Q Revenue From Mortgage Products $73.5M; 10/05/2018 – LendingTree’s Consumer Debt Outlook Finds Americans On Pace to Amass a Collective $4 Trillion in Consumer Debt by the End of 20; 13/03/2018 – H&R Block, LendingTree partner to empower clients to improve their financial well-being; 26/04/2018 – LendingTree 1Q Rev $181M; 11/05/2018 – LENDINGTREE,: PACT TO BUY OVATION CREDIT SERVICES; 24/05/2018 – Autotrader and Kelley Blue Book Team with LendingTree to Empower Shoppers with Auto Lending Options; 07/03/2018 LendingTree Releases Monthly Mortgage Offer Report for February; 26/04/2018 – LendingTree 1Q EPS $2.12; 26/04/2018 – LendingTree 1Q Adj EPS $1.10

Analysts await LendingTree, Inc. (NASDAQ:TREE) to report earnings on July, 26. They expect $0.76 earnings per share, 0.00% or $0.00 from last year’s $0.76 per share. TREE’s profit will be $9.49 million for 80.49 P/E if the $0.76 EPS becomes a reality. After $0.51 actual earnings per share reported by LendingTree, Inc. for the previous quarter, Wall Street now forecasts 49.02% EPS growth.

Ratings analysis reveals 100% of LendingTree’s analysts are positive. Out of 3 Wall Street analysts rating LendingTree, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $116.0 while the high is $129.0. The stock’s average target of $121.67 is -50.27% below today’s ($244.675) share price. TREE was included in 3 notes of analysts from September 16, 2016. On Friday, September 16 the stock rating was maintained by Mizuho with “Buy”. The firm earned “Outperform” rating on Friday, November 18 by RBC Capital Markets. The company was initiated on Wednesday, February 8 by Oppenheimer.

More important recent LendingTree, Inc. (NASDAQ:TREE) news were published by: Bizjournals.com which released: “Congressman sues LendingTree CEO over home construction in Quail Hollow” on June 13, 2018, also Prnewswire.com published article titled: “LendingTree Completes Acquisition of Ovation Credit Services”, Prnewswire.com published: “LendingTree Reveals the Cities with the Highest Share of Vacation, Investment and Second Homes” on June 11, 2018. More interesting news about LendingTree, Inc. (NASDAQ:TREE) was released by: Globenewswire.com and their article: “New Research Coverage Highlights Fortuna Silver Mines, First Majestic Silver, Anheuser-Busch InBev SA/NV, Banco …” with publication date: June 07, 2018.

More recent Affimed N.V. (NASDAQ:AFMD) news were published by: Seekingalpha.com which released: “Affimed Therapeutics 2018 Q1 – Results – Earnings Call Slides” on May 15, 2018. Also Seekingalpha.com published the news titled: “Affimed Therapeutics’ (AFMD) CEO, Adi Hoess on Q1 2018 Results – Earnings Call Transcript” on May 15, 2018. Nasdaq.com‘s news article titled: “Affimed Reports Financial Results for First Quarter 2018” with publication date: May 15, 2018 was also an interesting one.

Among 8 analysts covering Affimed Therapeutics (NASDAQ:AFMD), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Affimed Therapeutics had 17 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Affimed N.V. (NASDAQ:AFMD) earned “Sell” rating by Zacks on Monday, August 10. Oppenheimer maintained Affimed N.V. (NASDAQ:AFMD) on Thursday, August 6 with “Outperform” rating. Wells Fargo initiated the stock with “Outperform” rating in Friday, December 4 report. The firm has “Hold” rating by Zacks given on Thursday, September 3. Leerink Swann downgraded the stock to “Market Perform” rating in Thursday, May 19 report. The stock of Affimed N.V. (NASDAQ:AFMD) has “Hold” rating given on Thursday, August 31 by Jefferies. The firm has “Buy” rating by Laidlaw given on Thursday, December 10. As per Friday, August 12, the company rating was downgraded by Leerink Swann. On Tuesday, April 12 the stock rating was initiated by BMO Capital Markets with “Outperform”. The stock of Affimed N.V. (NASDAQ:AFMD) earned “Hold” rating by Jefferies on Thursday, May 19.

LendingTree, Inc. (NASDAQ:TREE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: